← All trials
NCT05804227
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 20, 2023
- Primary completion
- Sep 22, 2025
- Completion date
- Sep 22, 2027
- First posted
- Apr 7, 2023
- Last posted
- Sep 13, 2023
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Texas at HoustonLead sponsor
- BioMed Valley Discoveries, IncCollaborator
- University of Texas at HoustonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.